Action plan to phase out consumption of HCFC is on track: Ramesh

New Delhi, Sep 16 (ANI): Union Environment and Forest Minister Jairam Ramesh said on Wednesday that India has developed a comprehensive Road Map and Action Plan to phase-out of production and consumption of Hydrochlorofluorocarbons (HCFCs) in various sectors.

Addressing the gathering during the 15th International Ozone Day here Ramesh said: “The Government of India has taken a number of policy measures, fiscal and regulatory, to encourage the early adoption of alternative technologies in this area by existing and new enterprises.”

Ramesh hailed the Montreal Protocol as the most successful international treaty to ever achieve universal participation.

“At a time when the world is trying to solve the problem of climate change, the International Ozone Day provided a timely reminder of how international cooperation can help to solve major global environmental problems,” Ramesh added.

India is one of the first developing countries to join the Montreal Protocol and pledge its commitment to protect the Ozone Layer.

As a part of the accelerated phase-out of CFCs, India has completely phased out the production and consumption of CFCs as on 1 August 2008, 17 months prior to the agreed schedule.

Ramesh informed that over 97percent of controlled Ozone Depleting Substances (ODS) have been phased out by the Montreal Protocol.

“The end of 2009 will mark another significant milestone in the history of its implementation, with the use of potent ODSs -CFCs, Carbon Tetra Chloride (CTC) and Halons, except pharmaceutical-grade CFCs used in the manufacture of Metered Dose Inhalers (MDIs) – being ceased completely,” he said

The CFCs required for manufacturing for MDIs used by Asthma and Chronic Obstructive Pulmonary Disease (COPD) patients are still available in India, a national transition strategy to phase them out by 2013 is currently under implementation.

“The Ministry of Environment and Forests (MoEF), with support from the Global Environment Facility (GEF) and the World Bank recently also launched the India: Chiller Energy Efficiency Project to accelerate the conversion of CFC-based chillers using new, more energy efficient technologies,” Ramesh said.

This year’s theme for the ozone day was ‘Universal participation – Ozone protection unifies the World.’ (ANI)

2009 H1N1 influenza vaccines well tolerated, induce strong immune response in adults

Washington, September 12 (ANI): Early results from various clinical trials of 2009 H1N1 influenza vaccines in healthy adults seem to be quite encouraging, say U.S. health experts.

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health in the U.S., has revealed that the early data from these trials suggest that 2009 H1N1 influenza vaccines are well tolerated, and induce a strong immune response in most healthy adults, when administered in a single unadjuvanted 15-microgram dose.

It has even congratulated the companies that have carried out these trials, which it claims are an important part of the ongoing worldwide effort to develop vaccines to protect the public from 2009 H1N1 influenza.

The National Institute of Allergy and Infectious Diseases is also conducting clinical trials of 2009 H1N1 influenza vaccines, produced by Sanofi Pasteur and CSL Limited.

The trials are testing two different dosages-15 micrograms versus 30 micrograms-and evaluating the immune response to one and two doses of these vaccines.

More than 2,800 people are said to be participating in the ongoing NIAID trials of these vaccines.

The institute says that preliminary analyses of early data from its trials align with the recently announced findings, and those to be announced imminently by other companies.

Additional data from the NIAID trials are forthcoming.

“However, on the basis of these strong early data, our results are consonant with other reports that a single 15-microgram dose of unadjuvanted 2009 H1N1 influenza vaccine is well tolerated and induces a robust immune response in healthy adults between the ages of 18 and 64. For adults aged 65 and older, the immune response to 2009 H1N1 influenza vaccine is somewhat less robust, as is the case with seasonal influenza vaccines,” the institute said in a press release.

“We note that the slight discrepancies seen in our trials between the Sanofi Pasteur and CSL Limited vaccines may be due to technical differences in the preliminary measurement of the amounts of antigen in the doses used in the clinical trial lots and the relatively limited numbers of samples studied to date, as well as the fact that our data are drawn from a very early time point after immunization,” the institute added. (ANI)

How addictive drugs influence learning and memory

Washington, Sep 10 (ANI): In a new study on mice, researchers have found why and how the use of addictive drugs take control of reward signals and influence neural processes associated with learning and memory.

The study could help explain how drug-associated memories, such as the place of drug use, drive and perpetuate the addiction.

It is known that the neurochemical dopamine, a key player in the brain’s reward system, is involved in the process of addiction.

Research has indicated that dopamine participates in neural processes associated with learning, such as the strengthening of neuronal connections, called synaptic potentiation.

Evidence has also implicated the hippocampus, a deep-brain structure that is critical for formation of new memories, in the development of drug addiction.

“Although addictive drugs like nicotine have been shown to influence the induction of synaptic potentiation, there has been little or no research in freely moving animals that monitors ongoing induction of synaptic potentiation by a biologically relevant drug dose,” explains senior author Dr. John Dani from the Department of Neuroscience at the Baylor College of Medicine in Houston, Texas.

The researchers recorded from the brains of freely moving mice while applying physiologically relevant concentrations of nicotine, the addictive component in tobacco.

The researchers found that nicotine induced synaptic potentiation correlated with the mice learning to prefer a place associated with the nicotine dose.

Importantly, these effects required a local dopamine signal within the hippocampus.

The finding reinforces the view that dopamine enables memory for specific events.

Overall, the results point to some intriguing possibilities about how drug-associated memories might contribute to behaviors associated with addiction.

“An animal’s memories or feelings about the environment are updated when the dopamine signal labels a particular event as important, new, and salient. Normally these memories help us to perform successful behaviors, but in our study, those memories were linked to the addictive drug.

When specific environmental events occur, such as the place or people associated with drug use, they are capable of cuing drug-associated memories or feelings that motivate continued drug use or relapse,” concluded Dani.

The study has been published in the latest issue of the journal Neuron. (ANI)

Metal catalysts in carbon nanotubes block critical signalling pathway in neurons

Washington, August 28 (ANI): In what may prove very useful in improving treatments for human neurological disorders, Brown University scientists have found out why carbon nanotubes tend to block a critical signalling pathway in neurons.

Writing about their findings in the journal Biomaterials, the researchers have revealed that it is not the tubes, but the metal catalysts used to form them, that are to blame.

They say that minute amounts of a metal called ‘yttrium’ may impede neuronal activity.

They add that the findings mean that carbon nanotubes without metal catalysts may be able to treat human neurological disorders, although other possible biological effects still need to be studied.

“It’s a problem we can fix. We can purify the nanotubes by removing the metals, so it’s a problem we can fix,” said Lorin Jakubek, a Ph.D. candidate in biomedical engineering and lead author of the paper.

Taking single-walled carbon nanotubes to the laboratory of Brown neuroscientist Diane Lipscombe, the research team zeroed in on ion channels located at the end of neurons’ axons.

These channels are gateways of sorts, driven by changes in the voltage across neurons’ membranes. When an electrical signal, known as an action potential, is triggered in neurons, these ion channels “open”, each designed to take in a certain ion.

One such ion channel passes only calcium, a protein that is critical for transmitter release and thus for neurons to communicate with each other.

In experiments using cloned calcium ion channels in embryonic kidney cells, the researchers found that nickel and yttrium, two metal catalysts used to form the single-walled carbon nanotubes, were interfering with the ion channel’s ability to absorb the calcium.

Lipscombe, who specializes in neuronal ion channels and is a corresponding author on the paper, pointed out that yttrium’s ionic radius is nearly identical to calcium’s, which is why it “gets stuck and prevents calcium from entering and passing through. It’s an ion pore blocker.”

The experiments showed that yttrium in trace amounts – less than 1 microgram per milliliter of water – may disrupt normal calcium signalling in neurons and other electrically active cells, an amount far lower than what had been thought to be safe levels.

With nickel, the amount needed to impede calcium signalling was 300 times higher.

“Yttrium is so potent that … a very low nanotube dose” would be needed to affect neuronal activity, said Robert Hurt, professor of engineering and a corresponding author on the paper.

Jakubek said she was surprised that the metals turned out to be the cause.

“Based on the literature, I thought it would be the nanotubes themselves,” she said. (ANI)

Synthetic protein-like molecule may protect against HIV infection

Washington, Aug 18 (ANI): Researchers have used the human immunodeficiency virus (HIV) and molecular engineering to design synthetic protein-like molecule, which may be able to put a stop to unwanted biological interactions between the cells.

The pioneering study may protect cells against HIV infection.

In a bid to control protein shape, Samuel Gellman, a chemistry professor and his University of Wisconsin-Madison research team, created a set of peptide-like molecules that were successful in blocking HIV infection of human cells in the laboratory.

Adjusting molecular blueprints, Gellman and his colleagues made small structural changes to the backbones of their synthetic molecules to improve stability while retaining the three-dimensional shape necessary to recognize and interact with the HIV gp41 protein.

The resulting molecules, named “foldamers”, are hybrids of natural and unnatural amino acid building blocks, a combination that allows the scientists to control shape, structure and stability with much greater precision than is currently possible with natural amino acids.

The team found that the interaction of synthetic molecules with a piece of HIV protein gp41 physically obstructs the virus from infecting host cells.

The findings have appeared online in the August 17 issue of the Proceedings of the National Academy of Sciences.

Interactions between proteins are not only fundamental to many biological processes, but also to infections like HIV and tumours.

“There’s a lot of information transfer that occurs when proteins come together, and one would often like to block that information flow,” said Gellman.

These synthetic molecules not only interrupt protein-protein interaction, but are also highly resistant to degradation by naturally occurring enzymes, which do not recognize their unusual structure. This means even a low dose of these molecules can remain effective for a longer time.

“We want to find an alternate language, an alternate way to express the information that the proteins express so that we can interfere with a conversation that one protein is having with another,” Gellman explains.

Gellman said the results of their study show that this type of approach could be very useful in designing molecules for antiviral therapies and other biomedical applications.

He said: “You don’t have to limit yourself to the building blocks that nature uses,” Gellman says.

“There’s a huge potential here because the strategy we use is different from what the pharmaceutical and biotech industries now employ.” (ANI)

Experimental drug found effective against anthrax poisoning

London, July 10 (ANI): An experimental drug called raxibacumab has been found to be effective in treating anthrax poisoning, say researchers.

“The results published today showed that a single dose of raxibacumab was highly effective as a treatment for inhalation anthrax in both rabbits and monkeys,” said Dr Sally D. Bolmer, R.A.C, lead author and Senior Vice President, Development and Regulatory Affairs, HGS.

“Raxibacumab acted quickly to provide a significant survival benefit to animals showing clinical signs of disease caused by exposure to a dose of aerosolized anthrax spores that was approximately 200 times the median lethal dose.

“We also note that the safety profile shown in healthy human volunteers provides support for use of raxibacumab in the clinical setting of immediately life-threatening inhalation anthrax disease,” she added.

The drug works by targeting anthrax toxins after they are released by the bacteria into the blood and tissues.

In an inhalation anthrax attack, people may not know they are infected with anthrax until the toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective.

“We are very proud that the importance of these data and the rigor and high quality of our scientists’ work have led to publication in The New England Journal of Medicine,” said Dr David C. Stump, Executive Vice President, Research and Development, HGS. Based on these results, we believe raxibacumab has the potential to be a significant step forward in the treatment of inhalation anthrax,” he added.

The study has appeared in the New England Journal of Medicine. (ANI)

Two dietary oils could reduce body fat in older diabetic women

Washington, July 8 (ANI): Two common dietary oil supplements, safflower oil and conjugated linoleic acid (CLA), have an inherent ability to reduce body fat in obese postmenopausal women with Type 2 diabetes, revealed a study.

Safflower oil is common cooking oil, while conjugated linoleic acid (CLA) is a compound naturally found in some meat and dairy products, which has been associated with weight loss in previous studies.

Both are composed primarily of polyunsaturated fatty acids, which are considered “good fats”, which, when consumed in proper quantities, could lead to a variety of health benefits.

By comparing the two oils, the researchers found that16 weeks of supplementation with safflower oil reduced fat in the trunk area, lowered blood sugar, and increased muscle tissue in the women participants.

On the other hand, conjugated linoleic acid supplementation for the same length of time reduced total body fat, and lowered the women’s body mass index (BMI).

The women, who participated in the study, took one type of oil for 16 weeks, followed by the other oil for an equal amount of time.

The participants were instructed not to change their diets or exercise patterns over the course of the study, so the research would measure the effects of only the supplementation.

“Making this subtle change in the intake of high-quality dietary fats in an effort to alter body composition is both achievable and affordable to postmenopausal women in the United States who are managing the difficult combination of obesity and diabetes,” said Martha Belury, professor of human nutrition at Ohio State University and senior author of the study.

One of the most surprising finding was that, in 16 weeks, these women could lose between about two pounds and four pounds of trunk fat simply by taking safflower oil supplements.

The study showed that CLA supplementation significantly decreased body mass index and total body fat over both diet periods.

“I never would have imagined such a finding. This study is the first to show that such a modest amount of a linoleic acid-rich oil may have a profound effect on body composition in women,” said Belury.

The dose of either oil taken each day was approximately 1 2/3 teaspoons.

Postmenopausal women tend to lose muscle at the same time that body fat accumulates toward their middle.

Thus, the research shows how dietary oils can complement lifestyle and medication in helping older diabetic women manage their health, said Belury.

The research has been published online, and is scheduled for later print publication, in the American Journal of Clinical Nutrition. (ANI)

Jackson may have been saved with antidote, says leading Brit doctor

London, June 28 (ANI): A leading British doctor has said the sad demise of Michael Jackson may have been averted had proper medical procedures been followed.

Dr Michael Serpell, leading expert on pain management at Glasgow University, said if the King of Pop was showing adverse effects, such as suppressed beathing, caused from painkiller Demerol, then he should have been given mouth to mouth resuscitation and a dose of Nalexone which acts as an antidote to Demerol.

“A dose of Nalexone completely wipes out the effects of Demerol. He would wake up and be breathing again. It’s life-saving. I have done it myself,” The Daily Express quoted Dr Serpell as saying.

“If we were giving this drug by injection we would give it in a secure setting such as a hospital as the risks are high. Doctors administering this should always have the antidote available to give in case of adverse reactions.

“Patients should be monitored very closely because the risk of overdose with this drug is significant. If there are signs that breathing is suppressed then the antidote should be given. Even if there were other drugs involved it is still worth giving, and there are antidotes to the other drugs which can be given too,” he added.

Dr Russell Newcombe, one of the countries’ leading drug experts, also said a combination of Demerol and its antidote may have worked as a safer alternative.

Dr Newcombe said: “It seems hard to understand why Jackson was given this drug when a combined pill with an antidote was available, particularly as he may not have been well.”

According to entertainment news website TMZ, the Thriller hitmaker got a shot of Demerol on Thursday, the day he died.

Other reports suggested the 50-year-old’s increased drug dependency made him take cocktails of various drugs.

Medical examiners in Los Angeles are yet to determine the cause of his sudden death, but officials confirmed Jackson was on prescription medication. (ANI)

Debt ridden Jackson ‘feared being killed if he didn’t perform London gigs’

London, June 27 (ANI): Michael Jackson was reportedly in constant fear about his mounting debts and worried about his comeback concerts in London, telling friends: “If I don’t tour they’ll kill me.”

The King Of Pop’s increased drug dependency was said to have begun taking its toll on the singer’s mental and physical health days before he died on Thursday.

Jackson, who was almost bankrupt at the time of his death, was claimed to have suffered further exhaustion stemming from rehearsals for his 50 show concerts, which were due to begin at O2 arena on July 13.

” Michael was convinced that if he didn’t perform in London he would die. He would say, ‘They will kill me’, but no one ever really understood who he was talking about. He seemed paranoid,” The Sun quoted a source as saying.

Another source close to him added: ” There were serious concerns for his mental health near the end – so much so that he was seeing a psychiatrist.

“He said he was being pushed into a corner and had an irrational fear that he would die or be killed if he didn’t perform in London. He kept saying that he had to do the concerts because he owed too much money.

“But all the time he was saying these things, his body was starting to shut down as he became more and more dependent on drugs.

“His friends say he signed his death warrant when he put pen to paper for the O2 shows. He wasn’t up to it physically or mentally.”

Jackson, 50, was speculated to have suffered a cardiac arrest due to a fatal dose of prescription drugs but medics are yet to determine the cause of his death. (ANI)

Cops to question Jacko’s personal physician

New York, June 27 (ANI): With initial autopsy results inconclusive, the investigation into Michael Jackson’s sudden death turned its focus towards a mysterious doctor who was with the King of Pop when his heart stopped.

Dr. Conrad Murray on Friday was poised to speak with detectives investigating whether the King of Pop was done in by a fatal dose of prescription painkillers, according to reports.

Cardiologist Murray has been identified as the medical expert who witnessed the 50-year-old icon’s final moments, reports The New York Daily News.

Murray, who was helping Jackson gear up for a grueling 50-show comeback tour, went off radar shortly after the singer was pronounced dead.

Investigators spoke with Murray briefly. Later they towed a BMW with Texas plates from the property near Sunset Blvd., a car registered to Murray’s sister.

Meanwhile, coroners have ruled out foul play surrounding Jacko’s death.

Spokesman Craig Harvey said “the cause of death has been deferred” until toxicological tests are completed. (ANI)

Biomarkers to predict brain tumour’s response to therapy identified

Washington, June 24 (ANI): A research team including an Indian origin scientist at Massachusetts General Hospital has found new biomarkers that may help in identifying patients with recurrent glioblastoma, or brain tumours.

It will help in predicting which patients would respond better to anti-vascular endothelial growth factor therapy, specifically cediranib, which is an investigational, oral agent that is administered once daily.

“We found that results from an advanced MRI scan taken just a day after starting treatment correlated with survival,” said lead researcher A. Gregory Sorensen, M.D., associate professor of radiology and health sciences and technology at Harvard Medical School, Massachusetts General Hospital.

“Combining MRI with blood biomarkers did an even better job of identifying patients who best responded to treatment.

“If this approach is validated in larger studies, we could use these tools to keep patients on therapies that their tumours respond to, and shift non-responders to other therapies much earlier,” Sorensen added.

Using a form of magnetic resonance imaging (MRI) that looked at the mechanism of action of the agent, the researchers were able to determine, even as early as after a single dose of cediranib, those patients who benefited from the agent and those who did not.

“Vascular normalization is an important mechanism of how these drugs work in cancer patients,” said Dr Rakesh K. Jain, Andrew Werk Cook professor of tumor biology at Harvard Medical School and director of the Edwin L. Steele Laboratory for Tumor Biology in the department of radiation oncology at Massachusetts General Hospital Cancer Centre, Boston.

“This is really a severe disease and being able to determine response at such an early point is helpful to tailor treatment,” he said.

“If we can predict those responding to antiangiogenic therapy early on, we may be able to define where the benefit would be,” he added.

The study appears in Cancer Research, a journal of the American Association for Cancer Research. (ANI)

Experimental drug leads to remarkable recoveries in 2 prostate cancer patients

London, June 20 (ANI): Two patients with inoperable prostate cancer have made remarkable recoveries after being given only a single dose of an experimental drug, called ipilimumab.

Rodger Nelson and Fructuoso Solano-Revuelta were diagnosed with advanced prostate cancer, and were part of a trial at the Mayo Clinic in Minnesota in the US that involved 108 patients, half of whom received the experimental drug.

The drug’s results were so impressive that researchers decided to release details of the two cases before the drug trial was complete.

Dr Eugene Kwon, the urologist who was in charge of their treatment, said that their progress had exceeded all expectations, and likened the results to the first pilot breaking the sound barrier.

“This is one of the Holy Grails of prostate cancer research. We have been looking for this for years,” the Independent quoted him as saying.

Initially, the pair were told that the disease had spread beyond the prostate-Nelson’s cancer was encroaching on the abdomen and Solano-Revuelta’s tumour was the size of a golf ball.

Usually, patients in such condition are told they may have only months to live, and are normally only offered palliative care.

But after one infusion of the drug ipilimumab, a monoclonal antibody that stimulates the immune system, given with conventional hormone therapy, their tumours shrank enough to be surgically removed.

Since then, both men have made a full recovery and returned to their businesses.

Although the trial is still going on, but the improvement of the two patients was so dramatic and unexpected that they were removed from the study so they could undergo curative surgery.

“Halfway through the trial we began seeing remarkable responses. Some patients had dramatic shrinkage of their tumours so practically all traces had disappeared. We had thought we might get some incremental delay in the progression of the cancer. It had not dawned on us that we might go from an inoperable tumour to an operable one. That just doesn’t happen,” said Kwon. (ANI)

Scientists suggest new animal model to test carcinogen risk

Washington, June 19 (ANI): Researchers at Oregon State University have suggested a new and improved method to test carcinogen risk.

They said that trout can be a superior animal model than laboratory rats, and other traditional methods of assessing the risk of carcinogens.

“The whole foundation of modern toxicology is that the dose makes the poison,” said George Bailey, an OSU distinguished professor emeritus of molecular and environmental toxicology.

“You can die from eating a few tablespoons of ordinary table salt at one time, but that doesn’t mean that table salt is a poison at the doses that humans normally consume.

“With compounds that we know can cause cancer, the real question is how much is too much.

“What we have found is that traditional approaches to making that evaluation, which are almost always based on studies done at very high doses with laboratory rodents, may not always give us answers that are reasonably accurate,” he added.

Researchers are usually trying to determine what can cause cancer at levels considered unacceptable.

However, the age-old problem they have faced is the cost and laboratory logistics making it virtually impossible to test millions of rats.

“When using rodents, it simply was not possible to study larger numbers of animals, the cost was too prohibitive,” said Linus Pauling Institute at OSU.

The Oregon State University researchers have revealed that rainbow trout may for many purposes be as or more accurate in determining what compounds, at what levels, can pose a risk of human cancer.

They have pioneered the use of trout for studies of this type for 40 years, and researchers believe that it may now be time to greatly expand the use of that research.

“We can do experiments with trout in large numbers at very low cost, about 5 percent of what a rodent study would cost,” she said.

“For most studies of carcinogens, exposing 2,000 rodents would be a huge project. For us, working with 2,000 trout is a pilot study,” she added.

The OSU scientists recently completed the largest study ever done with animals in toxicology, exposing 40,800 trout to what’s considered an “ultra-low” dose of dibenzo-a,l-pyrene, a chemical that can cause liver cancer and is part of a broad field of toxic compounds called polycyclic aromatic hydrocarbons, or PAHs.

The study determined that a tolerable threshold for human exposure to this toxic chemical would be 500 to 1,500 times higher than is outlined by the Environmental Protection Agency.(ANI)

Brit couple’s secret to 81yr marriage – regular rows!

London, May 27 (ANI): Frank and Anita Milford, aged 101 and 100 respectively, celebrated their 81st wedding anniversary yesterday. And, in case, you’re wondering what’s keeping their marriage alive, well the answer is pretty ‘mundane’ – regular rows!

The couple, who became man and wife in 1928, met at a YMCA dance in Plymouth, where they still live.

As for what’s keeping them stay so strong – they say that they still have daily squabbles.

“Not big rows, just the odd cross word. As far as I’m concerned, it’s healthy,” The Times quoted Anita, as saying.

However, as well as a little argument, “a little romance” is also essential.

“It’s our golden rule,” Mrs Milford said.
Couples these days don’t last long because they often don’t take enough time for each other. There isn’t enough respect – love is about give and take. Our advice to young couples would be to make time for a little romance every day,” she added.

Frank, a retired dockyard worker, said: “To win over your sweetheart you need a dose of old-fashioned chivalry and don’t let your standards slip.”

Their son, Frank Jnr, 74, said: “They spend most of their time together, with Dad almost completely deaf and blind, so it’s difficult for him. Mum is a chatterbox and nothing has changed there.” (ANI)

Arthritis drug may help fight flu

Washington, May 27 (ANI): A drug commonly used to treat rheumatoid arthritis has been found to reduce some of the severe symptoms of the Influenza A virus infection, say researchers from University of Maryland.

The study suggests that tempering the response of the body’s immune system to influenza infection may alleviate some of the more severe illness and even reduce mortality from this virus.

The team found that mice infected with the Influenza A virus responded favourably to a drug called Abatacept, which is commonly used to treat people with rheumatoid arthritis.

“We found that treating the mice with Abatacept minimized tissue damage caused by the immune response, but still enabled the body to rid itself of the virus,” said Dr Donna L. Farber, a professor of surgery and microbiology and immunology at the University of Maryland School of Medicine and the study’s senior author.

“The mice didn’t become as sick, recovered much faster and had much less damage to the lungs, compared to mice that weren’t given the drug.

“Moreover, treatment with Abatacept significantly improved survival for mice infected with a lethal dose of influenza virus,” she added.

The treated mice were 80 percent more likely to survive the infection, compared to 50 percent for those who weren’t treated.

“We believe that our findings are very significant because they provide a potential new treatment for infection by the influenza virus – one that would dampen the immune response, yet still preserve its protective effects,” said Dr. Farber.

The study appears in The Journal of Immunology. (ANI)

Green tea extract may help treat leukemia

Washington, May 27 (ANI): An active ingredient of green tea has been found effective in treating leukaemia patients, say researchers.

The study led by Mayo Clinic researchers has shown that patients could fairly tolerate high doses of the chemical epigallocatechin gallate (EGCG), derived from the green tea.

“We found not only that patients tolerated the green tea extract at very high doses (in capsule form), but many of them saw regression to some degree of their chronic lymphocytic leukemia,” said Dr Tait Shanafelt, Mayo Clinic hematologist and lead author of the study.

“The majority of individuals who entered the study with enlarged lymph nodes saw a 50 percent or greater decline in their lymph node size,” Shanafelt added.

The researchers hope that EGCG can stabilize CLL for early stage patients or perhaps improve the effectiveness of treatment when combined with other therapies.

After the success of the first trial, researchers have moved to the second phase of clinical testing. involving roughly the same number of patients. All will receive the highest dose administered from the previous trial.

The findings appear online in the Journal of Clinical Oncology. (ANI)

Herbal therapeutic Zyflamend shows promise in treatment of men at prostate cancer risk

Washington, May 23 (ANI): A novel herb-based therapeutic called Zyflamend has been found to be linked with minimal toxicity and no serious adverse events in men at high-risk for developing prostate cancer in its phase I clinical trial.

The trial was led by researcher from the Center for Holistic Urology at Columbia University Medical Center and NewYork-Presbyterian Hospital/Columbia.

Writing in the Journal of the Society for Integrative Oncology, the researchers revealed that 23 men aged 40-75 years, who were diagnosed with an increased risk of developing prostate cancer, were admitted into this prospective clinical trial to determine the safety and tolerability of Zyflamend when administered orally for 18-months, either alone or along with various dietary supplements.

“Since we know that men with HGPIN have an increased risk for developing prostate cancer, new strategies formulated to decrease cancer risk, prevent or delay surgery, and improve quality of life, will be greatly beneficial for these men,” said senior author of the study Dr. Aaron E. Katz, an associate professor of Urology at Columbia University College of Physicians and Surgeons.

The researchers say that basic science studies have suggested that Zyflamend may have an anti-inflammatory mechanism of action, and the agent has been found to be effective in decreasing the proliferation of prostate cancer in cell culture.

“Our results confirm that Zyflamend, in a dose of three times daily for up to 18-months, was well tolerated,” said Dr. Jillian L. Capodice, director of the Acupuncture Research and Integrative Clinical Service of the Department of Urology’s Center for Holistic Urology, at Columbia University College of Physicians and Surgeons. (ANI)

BP drugs should be given to everyone over 55 to reduce heart attack, stroke risk

London, May 20 (ANI): Individuals aged 55 and above should be given blood pressure lowering drugs- even if their reading is normal, a London-based expert says.

Epidemiology expert Professor Malcolm Law’s research found the medication cut the risk of heart attacks and strokes regardless of a person’s blood pressure.

Drugs such as beta blockers and ACE inhibitors reduce the chance of heart attacks by around a quarter and stroke by around a third, the British Medical Journal reports.

To reach the conclusion, research team from the Wolfson Institute of Preventive Medicine at Barts and The London School of Medicine analysed the findings of 147 blood pressure trials published between 1966 and 2007, involving 464,000 people.

The results show that using any one of the main classes of blood pressure lowering drugs at standard dose reduced fatal and non-fatal heart attacks by about a quarter and stroke by about a third. Heart failure was also reduced by about a quarter.
he reductions in disease were similar in people with and without clinical cardiovascular disease and regardless of blood pressure before treatment.

All the classes of blood pressure lowering drugs had a similar effect for a given reduction in blood pressure that was accurately predicted from epidemiological studies of blood pressure and subsequent disease with two exceptions-an extra protective effect of beta-blockers given shortly after a heart attack and a small additional effect of calcium channel blockers in preventing stroke.

Professor Malcolm Law said “The results show that blood pressure lowering drugs should be offered to anyone at sufficient risk to benefit from treatment, whatever their reason for being at risk.”

However, the exact age range for being most at risk of heart attack and stroke could not be defined precisely from this study, which only looked at randomised trials in people aged 60. (ANI)